Answers are grounded in this paper and cite their sources.
Integrated analysis reveals stability in renal function and low toxicity in HIV-1 patients with renal impairment treated with B/F/TAF.
Among 1069 people with HIV-1 and mild to moderate renal impairment at baseline treated with bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) across nine clinical trials, renal function remained generally stable over follow-up of up to 240 weeks. Renal adverse events were infrequent, and discontinuation due to renal toxicity was rare.
No takes yet. Share an insight, caveat, or question.
Post et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: